» Articles » PMID: 35095488

Vindoline Attenuates Osteoarthritis Progression Through Suppressing the NF-κB and ERK Pathways in Both Chondrocytes and Subchondral Osteoclasts

Overview
Journal Front Pharmacol
Date 2022 Jan 31
PMID 35095488
Authors
Affiliations
Soon will be listed here.
Abstract

Disruption of extracellular matrix (ECM) homeostasis and subchondral bone remodeling play significant roles in osteoarthritis (OA) pathogenesis. Vindoline (Vin), an indole alkaloid extracted from the medicinal plant , possesses anti-inflammatory properties. According to previous studies, inflammation is closely associated with osteoclast differentiation and the disorders of the homeostasis between ECM. Although Vin has demonstrated effective anti-inflammatory properties, its effects on the progression of OA remain unclear. We hypothesized that Vin may suppress the progress of OA by suppressing osteoclastogenesis and stabilizing ECM of articular cartilage. Therefore, we investigated the effects and molecular mechanisms of Vin as a treatment for OA and . In the present study, we found that Vin significantly suppressed RANKL-induced osteoclast formation and obviously stabilized the disorders of the ECM homeostasis stimulated by IL-1β in a dose-dependent manner. The mRNA expressions of osteoclast-specific genes were inhibited by Vin treatment. Vin also suppressed IL-1β-induced mRNA expressions of catabolism and protected the mRNA expressions of anabolism. Moreover, Vin notably inhibited the activation of RANKL-induced and IL-1β-induced NF-κB and ERK pathways. , Vin played a protective role by inhibiting osteoclast formation and stabilizing cartilage ECM in destabilization of the medial meniscus (DMM)-induced OA mice. Collectively, our observations provide a molecular-level basis for Vin's potential in the treatment of OA.

Citing Articles

Vindoline is a key component of Catharanthus roseus leaf juice extract prepared through an Ayurveda-based method for ameliorating insulin-resistant type 2 diabetes.

Singh P, Singh D, Patel M, Binwal M, Kaushik A, Mall M Protoplasma. 2025; .

PMID: 39794517 DOI: 10.1007/s00709-024-02026-w.


Small molecule inhibitors of osteoarthritis: Current development and future perspective.

Liu D, Li X, Zhang L, Hu B, Hu S, Zhang X Front Physiol. 2023; 14:1156913.

PMID: 37089415 PMC: 10119395. DOI: 10.3389/fphys.2023.1156913.


Zhuifeng tougu capsules inhibit the TLR4/MyD88/NF-κB signaling pathway and alleviate knee osteoarthritis: and experiments.

Xu X, Li N, Wu Y, Yan K, Mi Y, Yi N Front Pharmacol. 2022; 13:951860.

PMID: 36188596 PMC: 9521277. DOI: 10.3389/fphar.2022.951860.

References
1.
Xia B, Chen D, Zhang J, Hu S, Jin H, Tong P . Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014; 95(6):495-505. PMC: 4747051. DOI: 10.1007/s00223-014-9917-9. View

2.
Loeser R, Erickson E, Long D . Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008; 20(5):581-6. PMC: 2892710. DOI: 10.1097/BOR.0b013e3283090463. View

3.
Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H . The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 2014; 35(22):5721-30. DOI: 10.1016/j.biomaterials.2014.04.006. View

4.
Nakamura H, Hirata A, Tsuji T, Yamamoto T . Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003; 18(7):1198-205. DOI: 10.1359/jbmr.2003.18.7.1198. View

5.
Karsdal M, Leeming D, Dam E, Henriksen K, Alexandersen P, Pastoureau P . Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage. 2008; 16(6):638-46. DOI: 10.1016/j.joca.2008.01.014. View